Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 198-205

  Emory, Joshua F ^a   Seserko, Lauren A ^a   Marzinke, Mark A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Assay validation; CCR5 antagonist; HIV; LC MS MS; Maraviroc

Indexed keywords

ACETONITRILE; MARAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; INSTRUMENT VALIDATION; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; PARTICLE SIZE; PRACTICE GUIDELINE; PRECIPITATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CALIBRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES; REPRODUCIBILITY; STANDARD; VALIDATION STUDY;

CALIBRATION; CCR5 RECEPTOR ANTAGONISTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANES; HIV FUSION INHIBITORS; HUMANS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 84894655353     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.02.008     Document Type: Article

References (33)

1. Global report: UNAIDS report on the global AIDS epidemic 2012 http://www.unaids.org/en/resources/publications/2012.
2. Hardy W.D., Gulick R.M., Mayer H., et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010, 55(5):558-564.
3. Parra J., Portilla J., Pulido F., et al. Clinical utility of maraviroc. Clin Drug Invest 2011, 31(8):527-542.
4. Kromdijk W., Huitema A.D., Mulder J.W. Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother 2010, 11(7):1215-1223.
5. Liu R., Paxton W.A., Choe S., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86(3):367-377.
6. Moore J.P., Kitchen S.G., Pugach P., Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20(1):111-126.
7. Fätkenheuer G., Nelson M., Lazzarin A., et al. E, MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359(14):1442-1455.
8. Gulick R.M., Lalezari J., Goodrich J., et al. MOTIVATE study teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359(14):1429-1441.
9. Wilkin T.J., Gulick R.M. CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu Rev Med 2012, 63:81-93.
10. Neff C.P., Ndolo T., Tandon A., Habu Y., Akkina R. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010, 5(12):e15257.
11. Neff C.P., Kurisu T., Ndolo T., Fox K., Akkina R. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 2011, 6(6):e20209.
12. Malcolm K., Forbes C.J., Geer L., et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 2013, 68(3):678-683.
13. Abel S., Russell D., Whitlock L.A., Ridgway C.E., Nedderman A.N., Walker D.K. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008, 65(Suppl. 1):60-67.
14. Abel S., van der Ryst E., Rosario M.C., et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008, 65(Suppl. 1):5-18.
15. Walker D.K., Abel S., Comby P., Muirhead G.J., Nedderman A.N., Smith DA D.A. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005, 4:587-595.
16. AIDSinfo Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents available from, [accessed 01.25.2014]. http://aidsinfo.nih.gov/guidelines.
17. Fayet A., Béguin A., Zanolari B., et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(11-12):1057-1069.
18. D'Avolio A., Simiele M., Baietto L., et al. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. Ther Drug Monit 2010, 32(1):86-92.
19. Else L., Watson V., Tjia J., et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(19):1455-1465.
20. Brown K.C., Patterson K.B., Malone S.A., et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 2011, 203(10):1484-1490.
21. Takahashi M., Hirano A., Okubo N., Kinoshita E., Nomura T., Kaneda T. Development and application of a simple LC-MS method for the determination of plasma maraviroc concentrations. J Med Invest 2010, 57(3-4):245-250.
22. Brewer E., Felix T., Clarke P., Edgington A., Muirhead D. An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid. Biomed Chromatogr 2010, 24(12):1316-1323.
23. US Department of Health and Human Services UF, Center for Drug Evaluation and Research, Center for Veterinary Medicine Guidance for industry: bioanalytical method validation 2001, FDA, Rockville, MD, USA.
24. Seserko L.A., Emory J.F., Hendrix C.W., Marzinke M.A. The development and validation of an ultra high performance-liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis 2013, 5(22):2771-2783.
25. NCCLS Preliminary evaluation of quantitative clinical laboratory methods; approved guideline. NCCLS Document EP10-A2 2002, [Wayne, PA].
26. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at pictogram per milliliter concentrations. Anal Chem 1998, 70:882-889.
27. Malcolm R.K., Veazey R.S., Geer L., et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012, 56(5):2251-2258.
28. Forbes C.J., Lowry D., Geer L., et al. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 2011, 156(2):161-169.
29. Delobel P., Cazabat M., Saliou A., et al. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence. J Antimicrob Chemother 2013, 68(11):2506-2514.
30. HIV Prevention Trials Network Evaluating the safety and tolerability of antiretroviral drug regimens used as pre-exposure prophylaxis to prevent HIV infection in at-risk men who have sex with men and in at-risk women available from, [ID: NCT01505114 (accessed 11/14/2013)]. http://www.clinicaltrials.gov.
31. Massud I., Aung W., Martin A., et al. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol 2013, 87(16):8952-8961.
32. International Partnership for Microbicides First efficacy trial of a microbicide ring to prevent HIV is underway available from:, (accessed 04.23.13). http://www.ipmglobal.org/publications/first-efficacy-trial-microbicide-ring-prevent-hiv-underway.
33. The Research Foundation on Behalf of the State University of New York UaB CPQA guidelines for chromatographic method development and validation based on (and including) FDA guidelines dated May 2001; effective February 17, 2012. Clinical Pharmacology Quality Assurance and Quality Control version 4.0 2012.